Neuroimaging Biomarker

Alzheimer's sickness Biomarkers, with emphasis on cerebrospinal fluid biomarkers and neuroimaging. Mild Cognitive Impairment (MCI) of Neuroimaging-biomarkers permit an early diagnosis in preclinical levels of Alzheimer’s ailment. Biomarker changes in patients with late-onset AD, inclusive of findings from research using structural and practical magnetic resonance imaging (MRI), advanced MRI strategies (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and different neurochemical tracers, and CSF protein levels. The dynamic measures of these imaging biomarkers are used to predict the sickness progression inside the early levels and improve the evaluation of healing efficacy in these diseases in destiny clinical trials.

•              Neuroimaging Biomarkers in Personalized Medicine

•              Neuroimaging Genetics

    Related Conference of Neuroimaging Biomarker

    Neuroimaging Biomarker Conference Speakers